B A C K G R O U N D
BPH refers to proliferation of smooth muscle cells and epithelial cells mainly involving the transition zone of prostate gland. BPH presents with irritative and obstructive voiding symptoms. BPH causes BOO (Bladder Outlet Obstruction) by either static or dynamic mechanism. Static mechanism is by enlarged gland which can be cured by surgery. The second mechanism is dynamic which responds to pharmacological management especially with ALPHA blocker. Regardless of the exact proportion of epithelial to stromal cells in the hyperplastic prostate, there is no question that prostatic smooth muscle represents a significant volume of gland. Smooth muscle is one of the dominant cellular constituents in of BPH, accounting for 40% of the area density of hyperplastic prostate. (1) Active smooth muscle tone in the human prostate is regulated by adrenergic nervous system. Alpha 1a is the most abundant adrenergic receptor subtype present in human prostate. Moreover alpha 1 a receptor clearly mediates active tension in human prostatic smooth muscle. Alpha 1 blocker inhibits smooth muscle contraction and thus relieves dynamic component of BOO caused by BPH. (2) Tamsulosin is once daily administered alpha 1 blocker that exhibits some modest degree of selectivity for alpha 1 a receptor. Although the current medical therapy, alpha 1 blocker alone or in combination with 5 alpha reductase inhibitor, for BPH-LUTS is effective, it has potential side effects on sexual function like retrograde ejaculation/anejaculation. Incidence of abnormal ejaculation was 30% and erectile dysfunction was 6% in those patients treated with tamsulosin. (3) BPH and ED are both occurring in the old aged men with incidence increasing as age increases further. Rationale for the use of PDE-5 inhibitor in the treatment of men with BPH/LUTS was initially based on demographic data showing the frequent occurrence of both ED and LUTS in men as they age. This raised the possibility of a common underlying mechanism at least contributing to both processes. Immunohistochemical studies showed that PDE-5 receptor is located in endothelial cells and smooth muscle cells of blood vessels of lower urinary tract. Blockage of these receptors leads to bladder neck relaxation. Mechanism of action of Tadalafil, a long acting PDE-5 inhibitor, for the treatment of men with BPH-LUTS is associated with NO/CGMP/protein kinase G pathway leading to smooth muscle relaxation in different lower urinary tract tissues in bladder, urethra, prostate and supporting vasculature beside increased blood perfusion to pelvic area and modulation of sensory stimuli from this area. However, in the studies so far available, there have been no significant changes in Qmax, suggesting that the effects of PDE-5I is alone may be either more focused on bladder muscle function than on prostatic tissue or that the effects are more profound on storage symptoms than on bladder outflow obstruction itself.
M E T H O D S
We analysed 60 patients of BPH (Benign Prostatic Hyperplasia) with LUTS (Lower Urinary Tract Symptoms) with baseline parameters as international prostate symptom score (IPSS), QMAX (maximum urinary flow velocity), PVR (Post Voidal Residual urine volume), for a period of 6 months. They were divided in to two groups, one group receiving only alpha blockers, other group receiving only PDE -5 inhibitor (Phosphodiesterase type 5 inhibitor/PDE-5I) tadalafil in treatment of LUTS due to BPH. These patients were reviewed at 1, 3, 6 months interval with above mentioned parameters.
Inclusion Criteria
Male more than 45 years with LUTS due to BPH; that is male more than 45 years having either irritative (increased frequency, urgency, dysuria) or having obstructive LUTS (hesitancy, strain to void, thin stream of urine, intermittency) All these three parameters were recorded and reviewed at 1, 3, 6 months.
Exclusion Criteria

R E S U L T S
Of the 60 patients studied (55) the results clearly show that PDE-5Is are better than alpha blockers in the treatment of LUTS due to BPH in this populations. (Alpha Blocker-Group-I, PDE-5I -Group -II). (4) . FDA has been prescribing tadalafil (5 mg) for LUTS. This drug act by up regulation of no / cGMP pathway. They also reverse norepinephrine and endothelin induced prostate tissue contraction. By this way tension in the prostate tissue and capsule are reduced. (5) The alpha blockers act via alpha -1 adrenergic receptors which are abundant in the bladder neck, stroma, prostate capsule. This dynamic part leads to obstruction to the urine outflow. So it is almost that BPH and ED are linked to some extent and share pathophysiological pathways. Tadalafil can be used for both LUTS and ED but to treat subclinical ED treatment is not approved. Patients with mild to moderate LUTS, tadalafil should be recommended as the drug of choice. BPH/LUTS and ED both impact the quality of life of an individual patient. Alpha 1 blockers, which are standard of care for BPH/LUTS, have not shown consistent improvement in the erectile function, though there are few studies that report improvement. PDR-5 inhibitors, which are standard of care for treatment of ED, have been shown to cause a significant improvement in LUTS in patients with BPH in various studies, along with remarkable effect on erectile function, which has led to US-FDA approval of tadalafil for treatment of LUTS consistent with BPH with or without ED. After the first clinical report in 2002 of improvement in LUTS in men given sildenafil for their ED, (6) there has been explosion of interest in the role of PDE-5 inhibitors as a treatment of LUTS, and in particular, for the management of many men with both condition. Scientific basis is rapidly becoming stronger and there is now a good level 1 evidence from various clinical trials clearly showing improvements of LUTS after treatment with PDE-5 inhibitors.
The first RCT published to elucidate the impact of PDE-5 inhibitors was by Mcvary. (7) This was the first proper RCT, 12-week double blind placebo-controlled trial, showing improvement in both ED and IPSS score in PDE-5 inhibitors treated patients vs placebo. Second trial of Mcvary (7) was also double blind, placebo controlled, RCT evaluating the efficacy of Tadalafil. It included first a 4 wks. washout phase to reduce the placebo effect and reversion to mean phenomenon. Baseline IPSS score in Tadalafil arm improved from 17.5 to 13.3 while in placebo arm improved from 18.3 to 16.1. This study showed that men in Tadalafil group were more likely to show a 3-point or greater improvement in IPSS by 12 wks than in men placebo group (60.9% vs 42.7%) indicating NNT (number needed to treat) of 5.5 Roehrborn (8) RCT, double blind placebo controlled trial for tadalafil also gave similar results. Further good quality studies have confirmed the benefits of PDE-5 inhibitors. Tadalafil has become the dominant agent because of its half-life and convenient 5 mg daily dose and now has been licensed widely for prescription foe male LUTS. Analysis of pooled data of 1500 men in 4 international RCTs suggested that Tadalafil showed consistent efficacy compared with placebo (9) across multiple subgroups -for example, age, prostate volume, symptom severity. (10) Similar responses were shown in men with or without ED. (11) 
C O N C L U S I O N S
Though BPH associated LUTS and ED are epidemiologically linked and share common pathophysiological pathways, there is an as yet undetermined link between BPH-LUTS and ED. There is now good Level 1 evidence of a beneficial effect of PDE-5I on urinary symptoms, though PDE-5I alone do not improve flow rates as the mechanisms of effect are still unclear and are subject of extensive research because so many other body systems are also affected. Our study concludes that PDE-5 inhibitor (Tadalafil) should be preferred over alpha blockers in treating LUTS due to BPH as PDE-5 inhibitors are found to be more efficacious than alpha blocker with lesser incidences of side-effects. It is likely that PDE-5I will be valuable, especially for men with BPH-LUTS and significant ED, though further data on safety and cost effectiveness is needed.
